Italy-based Rottapharm Biotech is seeking more domestic investors to help fund development of a vaccine against SARS-CoV-2, as reported in the Financial Post.
"We hope to be able to bring on board other private and institutional investors," commented CEO Lucio Rovati, adding "it is essential that our country is also directly involved in the development of a vaccine resulting from Italian research."
The remarkes came after the company pledged €3 million towards testing for a vaccine called Covid-eVax that was launched in February by biotech company Takis, which is based in Rome.
The funds for Takis, which was founded by a group of biologists and researchers at Merck & Co.'s R&D arm, will go towards producing doses for the first clinical trials which will start in the autumn, Rovati said.
Preliminary results are expected in March next year, he added.
To read more NewsPoints articles, click here.